Piper Sandler Maintains Overweight on Palisade Bio, Lowers Price Target to $16

Benzinga · 2d ago
Piper Sandler analyst Yasmeen Rahimi maintains Palisade Bio (NASDAQ:PALI) with a Overweight and lowers the price target from $25 to $16.